Spots Global Cancer Trial Database for respiratory tract diseases
Every month we try and update this database with for respiratory tract diseases cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Real World Registry for Use of the Ion Endoluminal System | NCT06004440 | Lung Cancer Multiple Pulmon... Lung Neoplasms Respiratory Tra... Thoracic Neopla... Neoplasms by Si... Neoplasms Lung Diseases Respiratory Tra... | Ion Endoluminal... | 18 Years - | Intuitive Surgical | |
| Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy | NCT02984761 | Lung Neoplasm | Stereotactic Ra... Anatomic Pulmon... | 18 Years - | VA Office of Research and Development | |
| Real World Registry for Use of the Ion Endoluminal System | NCT06004440 | Lung Cancer Multiple Pulmon... Lung Neoplasms Respiratory Tra... Thoracic Neopla... Neoplasms by Si... Neoplasms Lung Diseases Respiratory Tra... | Ion Endoluminal... | 18 Years - | Intuitive Surgical | |
| Apatinib in the Treatment of Patients With EGFR T790M-Negative NSCLC | NCT03389256 | Lung Diseases Neoplasms Respiratory Tra... Thoracic Neopla... Non-Small-Cell ... | Apatinib EGFR-TKI | 18 Years - 75 Years | Sichuan Cancer Hospital and Research Institute | |
| Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC) | NCT01999985 | Lung Cancer Non-small Cell ... | Dasatinib - 1A Afatinib - 1A Dasatinib - 1B Afatinib - 1B | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLC | NCT04371796 | Lung Diseases Neoplasms Respiratory Tra... Thoracic Neopla... Non-small-cell ... | Sintilimab inje... | 18 Years - 75 Years | Sichuan Cancer Hospital and Research Institute | |
| A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer | NCT01039948 | Carcinoma, Non-... Lung Neoplasms Lung Cancer Respiratory Tra... | AV-299 + gefiti... Gefitinib | 18 Years - | AVEO Pharmaceuticals, Inc. | |
| Etiologies, Investigations and Outcomes of Patients Presenting With Hemoptysis | NCT02913365 | Hemoptysis Haemoptysis Lung Disease Pneumonia Tuberculosis Bronchiectasis Respiratory Tra... Respiratory Tra... Bronchitis Mycobacterium I... Bronchial Disea... Pulmonary Hemor... Signs and Sympt... Signs and Sympt... Pathologic Proc... Mycosis Hemorrhage Lung Cancer Pulmonary Embol... Arteriovenous F... | 18 Years - | Université de Sherbrooke | ||
| A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) | NCT03157128 | Non-Small Cell ... Medullary Thyro... Colon Cancer Any Solid Tumor | LOXO-292 | 12 Years - | Eli Lilly and Company | |
| A Phase I Study of iPS Cell Generation From Patients With COPD | NCT01860898 | Thoracic Diseas... Respiratory Tra... Cancer of Lung Cancer of the L... Lung Cancer Lung Diseases, ... COPD Pulmonary Emphy... Neoplasms, Lung Neoplasms, Pulm... Pulmonary Cance... Pulmonary Neopl... Carcinoma, Non-... Carcinoma, Smal... | Skin Biopsy | 18 Years - | Mayo Clinic | |
| A Phase I Study of iPS Cell Generation From Patients With COPD | NCT01860898 | Thoracic Diseas... Respiratory Tra... Cancer of Lung Cancer of the L... Lung Cancer Lung Diseases, ... COPD Pulmonary Emphy... Neoplasms, Lung Neoplasms, Pulm... Pulmonary Cance... Pulmonary Neopl... Carcinoma, Non-... Carcinoma, Smal... | Skin Biopsy | 18 Years - | Mayo Clinic | |
| Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLC | NCT04371796 | Lung Diseases Neoplasms Respiratory Tra... Thoracic Neopla... Non-small-cell ... | Sintilimab inje... | 18 Years - 75 Years | Sichuan Cancer Hospital and Research Institute | |
| A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) | NCT02941601 | Locally Advance... Metastatic Squa... | Necitumumab Gemcitabine Carboplatin | 18 Years - | Eli Lilly and Company | |
| Observational Study of Patients With Locally Advanced or Metastatic NSCLC (Non-Small Cell Lung Cancer) | NCT03053297 | Carcinoma, Non-... | Patient Reporte... | 18 Years - | AstraZeneca | |
| Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung) | NCT02134015 | Lung Cancer Non-small Cell ... | Patritumab Erlotinib Placebo | 20 Years - | Daiichi Sankyo | |
| Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer | NCT05297734 | End of Life Cancer | Receive technol... Receive redesig... | 21 Years - | Stanford University | |
| A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy | NCT05941897 | Advanced or Met... | Ceralasertib Durvalumab | 18 Years - | AstraZeneca | |
| Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II and IIIA Non-small Cell Lung Cancer | NCT02904954 | Carcinoma, Non-... | Durvalumab Durvalumab plus... | 18 Years - | Weill Medical College of Cornell University | |
| Phase III Trial to Evaluate the Elortinib vs Gefitinib in Advanced NSCLC With EGFR Exon 19 or 21 Mutations | NCT01024413 | Thoracic Neopla... | erlotinib gefitinib | - | Chinese Society of Lung Cancer | |
| Real World Registry for Use of the Ion Endoluminal System | NCT06004440 | Lung Cancer Multiple Pulmon... Lung Neoplasms Respiratory Tra... Thoracic Neopla... Neoplasms by Si... Neoplasms Lung Diseases Respiratory Tra... | Ion Endoluminal... | 18 Years - | Intuitive Surgical | |
| A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) | NCT02941601 | Locally Advance... Metastatic Squa... | Necitumumab Gemcitabine Carboplatin | 18 Years - | Eli Lilly and Company | |
| Safety and Efficiency of the YEARS Algorithm Versus Computed Tomography Pulmonary Angiography Alone for Suspected Pulmonary Embolism in Patients With Malignancy | NCT04657120 | Pulmonary Embol... Embolism Embolism and Th... Vascular Diseas... Cardiovascular ... Lung Diseases Respiratory Tra... Cancer Diagnosis | YEARS algorithm CTPA | 18 Years - | University Hospital, Brest | |
| First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases | NCT03653546 | Non-small Cell ... EGFR Gene Mutat... Brain Metastase... | AZD3759 Erlotinib Gefitinib | 18 Years - | Alpha Biopharma (Jiangsu) Co., Ltd. | |
| First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases | NCT03653546 | Non-small Cell ... EGFR Gene Mutat... Brain Metastase... | AZD3759 Erlotinib Gefitinib | 18 Years - | Alpha Biopharma (Jiangsu) Co., Ltd. | |
| A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors | NCT04644315 | Neoplasms Colorectal Neop... Melanoma Pancreatic Neop... Sarcoma Ovarian Neoplas... Brain Neoplasms Thyroid Neoplas... Neuroendocrine ... Cholangiocarcin... Salivary Gland ... Head and Neck N... Thyroid Cancer,... Lymphoma, Large... Neoplasms by Si... Respiratory Tra... Thoracic Neopla... Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Intestinal Neop... Gastrointestina... Digestive Syste... Digestive Syste... Gastrointestina... Colonic Disease... Intestinal Dise... Central Nervous... | Alectinib | 18 Years - | Hoffmann-La Roche | |
| The EPIC Trial The Elderly Patient Individualized Chemotherapy Trial | NCT03402048 | Stage IV, NSCLC Lung Neoplasms Bronchial Neopl... Carcinoma, Bron... Lung Diseases Neoplasms Respiratory Tra... Respiratory Tra... Thoracic Neopla... | Carboplatin Gemcitabine Pemetrexed Docetaxel Vinorelbine | 70 Years - | University of Turin, Italy | |
| (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC | NCT05153408 | Lung Neoplasm Carcinoma, Non-... Respiratory Tra... Neoplasms Neoplasms by Si... Lung Diseases Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Adenocarcinoma Carcinoma Neoplasms by Hi... Neoplasms, Nerv... EGFR C797S EGFR C797A EGFR L858R EGFR Exon 19 De... EGFR Gene Mutat... EGF-R Positive ... EGFR Mutation R... EGFR Activating... Thoracic Neopla... Antineoplastic ... Protein Kinase ... EGFR C797G EGFR C797X Non Small Cell ... | BLU-701 osimertinib carboplatin pemetrexed | 18 Years - | Blueprint Medicines Corporation | |
| A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors | NCT03899792 | Medullary Thyro... Infantile Myofi... Infantile Fibro... Papillary Thyro... Soft Tissue Sar... | LOXO-292 | 6 Months - 21 Years | Eli Lilly and Company | |
| A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer | NCT01039948 | Carcinoma, Non-... Lung Neoplasms Lung Cancer Respiratory Tra... | AV-299 + gefiti... Gefitinib | 18 Years - | AVEO Pharmaceuticals, Inc. | |
| A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors | NCT04644315 | Neoplasms Colorectal Neop... Melanoma Pancreatic Neop... Sarcoma Ovarian Neoplas... Brain Neoplasms Thyroid Neoplas... Neuroendocrine ... Cholangiocarcin... Salivary Gland ... Head and Neck N... Thyroid Cancer,... Lymphoma, Large... Neoplasms by Si... Respiratory Tra... Thoracic Neopla... Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Intestinal Neop... Gastrointestina... Digestive Syste... Digestive Syste... Gastrointestina... Colonic Disease... Intestinal Dise... Central Nervous... | Alectinib | 18 Years - | Hoffmann-La Roche | |
| Phase III Trial to Evaluate the Elortinib vs Gefitinib in Advanced NSCLC With EGFR Exon 19 or 21 Mutations | NCT01024413 | Thoracic Neopla... | erlotinib gefitinib | - | Chinese Society of Lung Cancer | |
| Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy | NCT02984761 | Lung Neoplasm | Stereotactic Ra... Anatomic Pulmon... | 18 Years - | VA Office of Research and Development | |
| Apatinib Combined With SHR-1210 Injection in the Treatment of Patients With Removable IB-IIIA NSCLC | NCT04133337 | Lung Diseases Neoplasms Respiratory Tra... Thoracic Neopla... Non-small-cell ... | Apatinib SHR-1210 | 18 Years - 75 Years | Sichuan Cancer Hospital and Research Institute | |
| Efficacy and Safety Study of Benralizumab for Patients With Severe Nasal Polyposis | NCT03401229 | Nasal Polyposis | Benralizumab 30... Matching placeb... | 18 Years - 75 Years | AstraZeneca | |
| Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC) | NCT01999985 | Lung Cancer Non-small Cell ... | Dasatinib - 1A Afatinib - 1A Dasatinib - 1B Afatinib - 1B | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors | NCT03899792 | Medullary Thyro... Infantile Myofi... Infantile Fibro... Papillary Thyro... Soft Tissue Sar... | LOXO-292 | 6 Months - 21 Years | Eli Lilly and Company | |
| Efficacy and Safety Study of Benralizumab for Patients With Severe Nasal Polyposis | NCT03401229 | Nasal Polyposis | Benralizumab 30... Matching placeb... | 18 Years - 75 Years | AstraZeneca | |
| International Lung Screen Trial (ILST) | NCT02871856 | Non-small Cell ... Lung Neoplasms Respiratory Tra... Thoracic Neopla... Neoplasms by Si... Neoplasms Lung Diseases Respiratory Tra... Smokers at Risk... | Low dose CT | 55 Years - 80 Years | The University of Queensland | |
| Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer | NCT01594398 | Lung Cancer Non Small Cell ... Breast Cancer Estrogen Recept... | entinostat entinostat Erlotinib Erlotinib Exemestane Exemestane | 18 Years - 90 Years | Syndax Pharmaceuticals | |
| Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II and IIIA Non-small Cell Lung Cancer | NCT02904954 | Carcinoma, Non-... | Durvalumab Durvalumab plus... | 18 Years - | Weill Medical College of Cornell University | |
| Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC | NCT06376084 | Carcinoma, Non-... Lung Neoplasms Respiratory Tra... Thoracic Neopla... Neoplasms by Si... Neoplasms Lung Diseases Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... | 18 Years - | AstraZeneca | ||
| Apatinib Combined With SHR-1210 Injection in the Treatment of Patients With Removable IB-IIIA NSCLC | NCT04133337 | Lung Diseases Neoplasms Respiratory Tra... Thoracic Neopla... Non-small-cell ... | Apatinib SHR-1210 | 18 Years - 75 Years | Sichuan Cancer Hospital and Research Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
